



# European Centre for Disease Prevention and Control How to improve vaccination programme monitoring

Pier Luigi Lopalco, Head of Vaccine Preventable Disease Programme

Luxembourg, 16 October 2012

### Elements of vaccination programme monitoring and available tools



#### information sharing at EU level:

#### An added value?

disease epidemiology

vaccine uptake

immunisation coverage

vaccine effectiveness

vaccine safety

behaviour monitoring

surveillance systems

event based surveillance

burden of disease tools

vaccine registries

vaccine coverage data collection

sero-surveys


ad-hoc studies

database linkage

behavioural science studies


#### **The Vaccination Paradox**






### Collecting data at sub-national level notified measles cases 2009 – 2011







- Identify cross-border issues
- Better monitoring the elimination efforts



### Coverage for one dose of MMR in EU 2000-2010



	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
Austria	74.7	78.5	78.5	78.8	73.5	91	80	77	83	76	
Belgium	82.2	82.2	82.2	82.2	82.2	88	91.9	91.9		94	
Bulgaria	88.6	90.1	92.1	95.5	94.7	96.2	95.7	96	95.9		
Cyprus	85	85	85	86	86.3	86.3	87	87	87		
Czech Republic	98	98	99	99.1	96.9						
Denmark	100	94	102.4	96	96	95	100			Lh	
Estonia	93	94.7	95.2	95.2	95.5	95.9			hil		
Finland	96	96	95.8	97	97			who	ייט ג		
France	84	85	85	86	QC			111			
Czech Republic  Denmark  Estonia  Finland  France  Germany  Greece  Hungary  Iceland  Italy  Latvia	91.7	91	91	92			N = N				
Greece	88	88	88			ate	U	$\circ$			
Hungary	100	100			-cir	100	$ \cap$	8			99.9
Iceland	90			. 12	CC''		$\mathcal{I}$				94
Ireland	70		~	5 NO	. 0	an-				90.4	90
Italy		-0	NO.		. 19						
Latvia		$\cap \cap \cup$		rtc	らょう			97	96.6	95.7	90.1
	$\Delta \Omega$	$00^{\circ}$	ah	Olc			96.6	96.9	97	96	96.1
$\Lambda$ $\circ$	1001		COV			4.در		96.2	96.2	96.2	96.2
41			O		4	86.01	94	79	78	82	72.55
					96.27	96.3		95.9	96.2	96.2	95.9
N				84	88	90	91	92	93	92	93
Ро			97.6	97.5	97.4	98.2	98.2	98.3		98.3	98.2
Por		8.0د	91.9	96.3	94.8	92.6	96.69	95	96.6	95	96
Rom		97.8	98.2	97.2	97.1	96.7		97.1			95
Slovak	98	98.6	98.6	98.6	98	98	98.4	98.8	99	99	98.5
Sloveni.	95.2	94	93.5	86.7	94		96.1	95.56	96	95	95
Spain	94	96	96.6	97.15	97.3	96.8	96.9	97.1	97.8	97.5	95.1
Sweden	94.2	88.5	95	95	94.5	95.4	95.4	96.2	96.2	96.7	96.5
UK	99	98.76	83	80	81	82.1	84.9	86.2	85.5	86	93

Source: WHO CISID


#### Detailed vaccine coverage data needed?



- In all EU countries MMR coverage for the second dose is lower than the first dose
- 14 countries are able to provide coverage data at sub-national level and in 8 of those countries significant variations between regions were observed
- Information on vaccine coverage in ethnic or other specific groups (including health care workers) is not routinely collected

## Japanese strategy to immunize the susceptible age groups






#### **Vaccine safety – the VAESCO project**



- Assessment of vaccine safety signals in specific studies
- VAESCO investigators from Public Health Institutes, National Regulatory Agencies and academic research groups in 14 EU/EEA MS.
- Available source population >40 million
- The network use data linkage of immunization registries and other health registries




#### Measuring vaccination effectiveness



- I-MOVE: a well established network and methodology which provided seasonal and pandemic vaccine effectiveness estimates for four consecutive influenza seasons (started in 2007, 11 study sites funded by ECDC)
- The **EU-Pneumo** network, set up in 2012. This project will allow comparing the pneumococcal vaccine impact in different countries, measuring the effectiveness of different vaccination schedules, identifying risk factors for vaccine failure, and collecting evidence of serotype replacement since vaccine introduction. Currently there are 12 institutions from nine countries involved.

#### **Studying behaviours**









religious/philosophical beliefs







followers of conspiracy theories

#### Monitoring the process towards a goal



vaccine uptake

disease epidemiology

95%

immunisation coverage

vaccine effectiveness

vaccine safety

behaviour monitoring



### Thank you

pierluigi.lopalco@ecdc.europa.eu